Alembic Ltd share price logo

Alembic Ltd (ALEMBICLTD)

₹101.650.4%

bell
Get free price alerts. Set up your Free investment account to get Live Prices. >
Overview
Fundamentals
Q3 '23 Results
Technicals
News and Events

Alembic Ltd share Performance

  • ₹100.25
    ₹102.8
    ₹101.65
    downward going graph

    1.38%

    Low

    Day's Volatility:2.51%

    High

    1.13%

    downward going graph
  • ₹66.3
    ₹107.65
    ₹101.65
    downward going graph

    34.78%

    Low

    52 Weeks Volatility:40.68%

    High

    5.90%

    downward going graph
1 Month Return+ 11.02 %
3 Month Return-1.17 %
1 Year Return+ 47.49 %
Previous Close₹101.25
Open₹102.05
Volume4.47L
Upper Circuit-
Lower Circuit-
Market Cap₹2,599.92Cr

Company Information

Alembic Ltd is one of India's most experienced manufactures of bulk drugs, pharmaceuticals, and formulations in human and animal healthcare. With a 100-year legacy of operations, they are committed to continually improving the quality of life and healthcare in over 75 countries worldwide. The ISO9002 and ISO14001 certified company manufacturing practices and facilities follow WHOGMP guidelines. Their product range include medicines, chemicals, bulk drugs such as penicillin, other antibiotics, and formulations. With factories in Vadodara, Gujarat, and Solan, Himachal Pradesh, the company has seen tremendous success over the years. From establishing a penicillin plant in 1961, launching of the top selling Erythromycin brand Althrocin in 1972 to manufacturing Cephalosporin C in 2001, Zero - a new generation no calories Sucralose Based Sugar Substitute in 2005, and setting up a formulation manufacturing facility in Baddi with a capacity of 900 million tablets and 600 liquid oral bottles in 2017, Alembic Ltd and its offerings have grown exponentially. Last year, the company acquired the Non-Oncology Business of Dabur Pharma Ltd and entered into a licensing agreement with UCB Belgium while adding new API facilities.

Share Price: ₹101.65 per share as on 18 May, 2024 04:01 PM
Market Capitalisation: ₹2,599.92Cr as of today
Revenue: ₹49.04Cr as on March 2024 (Q1 24)
Net Profit: ₹21.29Cr as on March 2024 (Q1 24)
Listing date: 04 Jan, 1995
Chairperson Name: Chirayu R Amin
OrganisationAlembic Ltd
HeadquartersVadodara
IndustryRealty
E-voting on sharesClick here to vote

Key events for Alembic Ltd

  • Alembic Plans to Launch 25 Drugs in US Generics Segment; Reports Strong Financial Results - 17 May, 2024

    Alembic Pharma is set to launch 25 new drugs in the US generics segment and target R&D spending of ₹550-₹600 crore for FY25. The company has reported strong financial results with a YoY increase in net sales and net profit for both Alembic Pharma and its standalone entity.

  • Alembic Ltd Stock Gains on Q4 Results Announcement - 15 May, 2024

    Alembic Ltd's stock gained 14.49% on high-frequency trading after the announcement of its Q4FY24 results. Alembic Pharma's revenue missed estimates but EBITDA beat expectations due to cost optimization measures. Analysts retain a HOLD rating with a decreased target price.

  • Alembic Reports Strong Q4 Results; Motilal Oswal Raises Earnings Estimates - 14 May, 2024

    Alembic Ltd's Q4FY24 net profit soared by 425% YoY to Rs 21 crore, while its total income rose by 30.7% YoY to Rs 51 crore. Additionally, Motilal Oswal raised the company's earnings estimates for FY25/FY26 and valued the stock on an SoTP-basis with a target price of INR 960, reiterating a neutral rating.

  • Alembic Plans to Launch 25 Products in US Generic Portfolio - 13 May, 2024

    Alembic Ltd reported a decent set of Q4 numbers and announced plans to ramp up their US generic portfolio with 25 product launches this year. The company does not plan any major capex, which should lead to improved margins.

  • Alembic Pharmaceuticals FY24 EPS Beats Expectations, Revenues Lag - 11 May, 2024

    Alembic Pharmaceuticals reported an 11% YoY increase in revenue to ₹62.6b and a net income of ₹6.16b, up 80% from FY23. The profit margin increased to 9.8%, driven by higher revenue. However, the revenue missed analyst estimates by 1.2%. Looking ahead, Alembic forecasts an average annual growth rate of 11% for the next three years compared to 10% for the Indian pharmaceutical industry. The company's shares are down 4.8% from a week ago.

  • Alembic Pharmaceuticals Posts Strong FY24 Results - 10 May, 2024

    Alembic Pharmaceuticals reports an 80% YoY growth in net profit to Rs 616 crore, with net sales rising 10% to Rs 6,229 crore and EBITDA surging 41% to Rs 961 crore. The India-branded business achieved 3% growth generating a topline of Rs 503 crore.

  • Alembic Pharma Reports Strong Q4 Results and FDA Approvals - 09 May, 2024

    Alembic Pharmaceuticals reports strong growth in Q4 FY24 with a YoY increase in net sales by 8% and net profit by 17%. The company also received multiple USFDA product approvals during the period April 1 to May 8. Alembic's India branded business achieved a 3% growth while the US Generics segment experienced a 19% growth YoY.

  • Alembic Pharmaceuticals Receives Establishment Inspection Report from US FDA - 07 May, 2024

    Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Oncology Formulation Facility, completing EIRs for all of its USFDA facilities.

  • Alembic Pharmaceuticals Receives Establishment Inspection Report from USFDA - 06 May, 2024

    The United States Food and Drug Administration has issued an establishment inspection report to Alembic Pharmaceuticals for its oncology facility in Gujarat. The EIR confirms that the company's formulation facility meets the regulatory standards of the US drug regulator. Alembic Pharmaceuticals has also announced that all of its USFDA facilities have received EIRs.

  • Alembic Pharmaceuticals CEO Has Net Worth of Rs 15850 Crore - 03 May, 2024

    Chirayu Amin, the chairman and CEO of Alembic Pharmaceuticals Ltd., has a real-time net worth of Rs 15850 crore as of May 3. The company gets more than a third of its annual revenue from the domestic market selling generic drugs.

Fundamentals of Alembic Ltd

Insights on Alembic Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 41.55 Cr → 51.08 Cr (in ₹), with an average increase of 18.7% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 61.4 Cr → 72.15 Cr (in ₹), with an average increase of 14.9% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ALEMBICLTD stock has moved up by 15.5%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 0.89% to 1.07% in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Zydus Lifesciences Ltd has given 107.0% return, outperforming this stock by 59.5%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 70.88% of holdings in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 121.7% return, outperforming this stock by 138.2%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 28.17% to 28.00% in Mar 2024 quarter

Alembic Ltd Valuation

Alembic Ltd in the last 5 years

  • Overview

  • Trends

Lowest (2.82x)

March 31, 2020

Today (9.68x)

May 17, 2024

Industry (214.31x)

May 17, 2024

Highest (14.97x)

January 24, 2018

LowHigh

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
70.88%
0.00
Foreign Institutions
1.07%
0.00
Mutual Funds
0%
0.00
Retail Investors
28%
0.00
Others
0.05%
0.00

Technicals of Alembic Ltd share

News & Events of Alembic Ltd

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Alembic Ltd shares.

Alembic Ltd (ALEMBICLTD) share price today is ₹101.65

Alembic Ltd is listed on NSE

Alembic Ltd is listed on BSE

  • Today’s highest price of Alembic Ltd is ₹102.8.
  • Today’s lowest price of Alembic Ltd is ₹100.25.

PE Ratio of Alembic Ltd is 9.68

PE ratio = Alembic Ltd Market price per share / Alembic Ltd Earnings per share

Today’s traded volume of Alembic Ltd(ALEMBICLTD) is 4.47L.

Today’s market capitalisation of Alembic Ltd(ALEMBICLTD) is ₹2599.92Cr.

Alembic Ltd(ALEMBICLTDPrice
52 Week High
₹107.65
52 Week Low
₹66.3

Alembic Ltd(ALEMBICLTD) share price is ₹101.65. It is down -5.57% from its 52 Week High price of ₹107.65

Alembic Ltd(ALEMBICLTD) share price is ₹101.65. It is up 53.32% from its 52 Week Low price of ₹66.3

Alembic Ltd(ALEMBICLTDReturns
1 Day Returns
0.4%
1 Month Returns
11.02%
3 Month Returns
-1.17%
1 Year Returns
47.49%